| Chk1-dependent slowing of S-phase progression protects DT40 B-lymphoma cells against killing by the nucleoside analogue 5-fluorouracil. | |
| | |
MedLine Citation:
|
PMID: 16619043 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Chk1 plays a crucial role in the DNA damage and replication checkpoints in vertebrates and may therefore be an important determinant of tumour cell responses to genotoxic anticancer drugs. To evaluate this concept we compared the effects of the nucleoside analogue 5-fluorouracil (5FU) on cell cycle progression and clonogenic survival in DT40 B-lymphoma cells with an isogenic mutant derivative in which Chk1 function was ablated by gene targeting. We show that 5FU activates Chk1 in wild-type DT40 cells and that 5FU-treated cells accumulate in the S phase of the cell cycle due to slowing of the overall rate of DNA replication. In marked contrast, Chk1-deficient DT40 cells fail to slow DNA replication upon initial exposure to 5FU, despite equivalent inhibition of the target enzyme thymidylate synthase, and instead accumulate progressively in the G1 phase of the following cell cycle. This G1 accumulation cannot be reversed rapidly by exogenous thymidine or removal of 5FU, and is associated with increased incorporation of 5FU into genomic DNA and severely diminished clonogenic survival. Taken together, these results demonstrate that a Chk1-dependent replication checkpoint which slows S phase progression can protect tumour cells against the cytotoxic effects of 5FU. |
| | |
Authors:
|
H M R Robinson; R Jones; M Walker; G Zachos; R Brown; J Cassidy; D A F Gillespie |
Related Documents
:
|
9357773 - Cell cycle-dependent expression of a glioma-specific chloride current: proposed link to... 16158973 - The role of p27 in controlling the oxygen-dependent checkpoint of mammalian cells in la... 18452183 - Oogenesis: prospects and challenges for the future. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2006-04-17 |
Journal Detail:
|
Title: Oncogene Volume: 25 ISSN: 0950-9232 ISO Abbreviation: Oncogene Publication Date: 2006 Aug |
Date Detail:
|
Created Date: 2006-08-31 Completed Date: 2006-09-28 Revised Date: 2011-11-02 |
Medline Journal Info:
|
Nlm Unique ID: 8711562 Medline TA: Oncogene Country: England |
Other Details:
|
Languages: eng Pagination: 5359-69 Citation Subset: IM |
Affiliation:
|
Beatson Institute for Cancer Research, Glasgow, UK. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Cell Cycle
/
drug effects,
physiology Cell Line, Tumor Cell Survival / drug effects DNA Damage DNA Replication Enzyme Activation Fluorouracil / toxicity* Humans Lymphoma, B-Cell Protein Kinases / metabolism* S Phase / drug effects, physiology* |
| Chemical | |
Reg. No./Substance:
|
51-21-8/Fluorouracil; EC 2.7.-/Protein Kinases; EC 2.7.11.1/Checkpoint kinase 1 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Apoptotic DNA fragmentation factor maintains chromosome stability in a P53-independent manner.
Next Document: Stat3 contributes to keloid pathogenesis via promoting collagen production, cell proliferation and m...